MEI Pharma Analyst Ratings
MEI Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/08/2023 | -71.15% | Jefferies | $0.4 → $0.1 | Downgrades | Hold → Underperform |
| 12/06/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/06/2022 | — | Truist Securities | Downgrades | Buy → Hold | |
| 03/25/2022 | 1054.07% | BTIG | $11 → $4 | Maintains | Buy |
| 03/25/2022 | 765.55% | Truist Securities | $8 → $3 | Maintains | Buy |
| 03/25/2022 | 1342.59% | HC Wainwright & Co. | $10 → $5 | Maintains | Buy |
| 03/25/2022 | 477.03% | Wells Fargo | $13 → $2 | Downgrades | Overweight → Equal-Weight |
| 03/25/2022 | 477.03% | Stifel | $6 → $2 | Downgrades | Buy → Hold |
| 03/25/2022 | 188.52% | Jefferies | $4 → $1 | Downgrades | Buy → Hold |
| 02/03/2022 | 1054.07% | Jefferies | → $4 | Initiates Coverage On | → Buy |
| 05/29/2020 | 4516.27% | SunTrust Robinson Humphrey | → $16 | Initiates Coverage On | → Buy |
| 02/13/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 12/20/2018 | 2785.17% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 07/27/2018 | 1919.62% | Stifel | $2.5 → $7 | Upgrades | Hold → Buy |
| 07/13/2018 | 3362.2% | SunTrust Robinson Humphrey | → $12 | Initiates Coverage On | → Buy |
| 06/06/2018 | — | Wells Fargo | Upgrades | Market Perform → Outperform | |
| 04/12/2018 | 1919.62% | Laidlaw & Co. | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变化 | 上一页/当前额定值 |
|---|---|---|---|---|---|
| 02/08/2023 | -71.15% | 杰富瑞 | 0.4 美元 → 0.1 美元 | 降级 | 持有 → 跑赢大盘 |
| 12/06/2022 | — | BTIG | 降级 | 买入 → 中性 | |
| 12/06/2022 | — | 信托证券 | 降级 | 买入 → 持有 | |
| 03/25/2022 | 1054.07% | BTIG | 11 美元 → 4 美元 | 维护 | 买 |
| 03/25/2022 | 765.55% | 信托证券 | 8 美元 → 3 美元 | 维护 | 买 |
| 03/25/2022 | 1342.59% | HC Wainwright & Co. | 10 美元 → 5 美元 | 维护 | 买 |
| 03/25/2022 | 477.03% | 富国银行 | 13 美元 → 2 美元 | 降级 | 超重 → 重量相等 |
| 03/25/2022 | 477.03% | Stifel | 6 美元 → 2 美元 | 降级 | 买入 → 持有 |
| 03/25/2022 | 188.52% | 杰富瑞 | 4 美元 → 1 美元 | 降级 | 买入 → 持有 |
| 2022 年 3 月 2 日 | 1054.07% | 杰富瑞 | → 4 美元 | 开启覆盖范围 | → 购买 |
| 05/29/2020 | 4516.27% | SunTrust 罗宾逊汉弗莱 | → 16 美元 | 开启覆盖范围 | → 购买 |
| 02/13/2019 | — | BTIG | 开启覆盖范围 | → 购买 | |
| 2018 年 12 月 20 日 | 2785.17% | HC Wainwright & Co. | → 10 美元 | 开启覆盖范围 | → 购买 |
| 07/27/2018 | 1919.62% | Stifel | 2.5 美元 → 7 美元 | 升级 | 持有 → 买入 |
| 07/13/2018 | 3362.2% | SunTrust 罗宾逊汉弗莱 | → 12 美元 | 开启覆盖范围 | → 购买 |
| 06/06/2018 | — | 富国银行 | 升级 | 市场表现 → 跑赢大盘 | |
| 04/12/2018 | 1919.62% | Laidlaw & Co. | → 7 美元 | 开启覆盖范围 | → 购买 |
What is the target price for MEI Pharma (MEIP)?
MEI Pharma（MEIP）的目标价格是多少？
The latest price target for MEI Pharma (NASDAQ: MEIP) was reported by Jefferies on February 8, 2023. The analyst firm set a price target for $0.10 expecting MEIP to fall to within 12 months (a possible -71.15% downside). 9 analyst firms have reported ratings in the last year.
杰富瑞于2023年2月8日公布了MEI Pharma（纳斯达克股票代码：MEIP）的最新目标股价。这家分析公司将目标价设定为0.10美元，预计MEIP将在12个月内降至-71.15％（可能下跌-71.15％）。去年有9家分析公司公布了评级。
What is the most recent analyst rating for MEI Pharma (MEIP)?
MEI Pharma（MEIP）的最新分析师评级是多少？
The latest analyst rating for MEI Pharma (NASDAQ: MEIP) was provided by Jefferies, and MEI Pharma downgraded their underperform rating.
MEI Pharma（纳斯达克股票代码：MEIP）的最新分析师评级由杰富瑞提供，MEI Pharma下调了表现不佳的评级。
When is the next analyst rating going to be posted or updated for MEI Pharma (MEIP)?
MEI Pharma（MEIP）的下一个分析师评级将在何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MEI Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MEI Pharma was filed on February 8, 2023 so you should expect the next rating to be made available sometime around February 8, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括浏览公开财务报表，与MEI Pharma的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月这样做一次，因此每家公司每年应该获得4次评级。MEI Pharma的最新评级是在2023年2月8日公布的，因此您应该预计下一个评级将在2024年2月8日左右公布。
Is the Analyst Rating MEI Pharma (MEIP) correct?
分析师评级 MEI Pharma (MEIP) 是否正确？
While ratings are subjective and will change, the latest MEI Pharma (MEIP) rating was a downgraded with a price target of $0.40 to $0.10. The current price MEI Pharma (MEIP) is trading at is $0.35, which is out of the analyst's predicted range.
虽然评级是主观的，而且会发生变化，但最新的MEI Pharma（MEIP）评级被下调，目标价为0.40美元至0.10美元。MEI Pharma（MEIP）目前的交易价格为0.35美元，超出了分析师的预期区间。